Dapagliflozin reduced the risk of all-cause mortality or worsening heart failure by 28% in patients with aortic stenosis undergoing transcatheter aortic valve implantation (TAVI), a new study has reported.
At one year, dapagliflozin reduced the primary composite outcome of all-cause mortality or worsening heart failure by 28% relative risk reduction (15.0% dapagliflozin vs 20.1% standard care; HR 0.72; 95% CI, 0.55–0.95; P = 0.02).
Worsening heart failure was reduced by 37% (9.4% vs 14.4%; subHR 0.63; 95% CI, 0.45–0.88), hospitalizations for heart failure by 32% (7.4% vs 10.7%; subHR 0.68; 95% CI, 0.46–0.99), and urgent heart failure visits requiring IV diuretics by 54% (2.8% vs 6.0%; subHR 0.46; 95% CI, 0.26–0.82).
Dapagliflozin also reduced the secondary outcome of cardiovascular death or heart failure hospitalization by 29% (10.1% vs 13.8%; subHR 0.71; 95% CI, 0.51–0.98). The total number of recurrent events—cardiovascular deaths and heart failure hospitalizations—was reduced by 33% (79 vs 121 events; rate ratio 0.67; 95% CI, 0.47–0.95).
A prespecified subgroup analysis was performed to assess the consistency of treatment effect, with key results summarized below.
Benefit in Patients with CV Risk Factors: In patients with type 2 diabetes, dapagliflozin reduced the primary outcome by 33% (15.2% vs 22.7%; HR, 0.63; 95% CI, 0.42–0.94). In those with hypertension, the primary endpoint outcome reduction was 24% (15.3% vs 20.2%; HR 0.73; 95% CI, 0.54–0.97).
Outcome in Patients with Cardiac Co-Morbidities: In patients with preserved left ventricular ejection fraction (LVEF >40%), dapagliflozin reduced primary outcome by 33% (14.1% vs 21.2%; HR 0.67; 95% CI, 0.50–0.91). Those with mild or no left ventricular hypertrophy also benefited, with a 29% event reduction (11.8% vs 16.1%; HR 0.72; 95% CI, 0.52–1.00).
Patients with atrial fibrillation had a 33% relative risk reduction (19.6% vs 29.2%; HR 0.63; 95% CI, 0.44–0.90).
Renal Function: In patients with impaired renal function (eGFR <60 ml/min/1.73 m²), dapagliflozin reduced primary outcome by 28% (17.3% vs 22.9%; HR 0.71; 95% CI, 0.49–1.03). Among those with preserved kidney function (eGFR ≥60), the risk was reduced by 26% (12.7% vs 17.3%; HR 0.72; 95% CI, 0.45–1.16).
Background Cardiovascular Therapy: Dapagliflozin reduced the composite outcome of death or worsening heart failure by 30% in patients receiving RAS inhibitors (12.4% vs 17.6%; HR 0.68; 95% CI, 0.47–0.99). While not statistically significant, similar trends were observed in patients on beta-blockers (19.2% vs 24.9%; HR 0.74; 95% CI, 0.50–1.10) and diuretics (16.8% vs 21.6%; HR 0.75; 95% CI, 0.56–1.02), indicating a consistent treatment effect across therapies.
The results of DapaTAVI trial highlight a promising role for the SGLT2 inhibitor, dapagliflozin, in patients undergoing TAVI, particularly those with coexisting heart failure or renal dysfunction.
Reference: Díez-Villanueva, Pablo, et al. “Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation.” The New England Journal of Medicine, vol. 390, no. 13, 2025, pp. 1234–1245. DOI: 10.1056/NEJMoa2500366.
Abbreviations: TAVI – Transcatheter Aortic Valve Implantation, DapaTAVI – Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation, HR – Hazard Ratio, subHR – Subdistribution Hazard Ratio, CI – Confidence Interval, eGFR – Estimated Glomerular Filtration Rate, LVEF – Left Ventricular Ejection Fraction, IV – Intravenous, SGLT2 – Sodium-Glucose Cotransporter 2, RAS – Renin-Angiotensin System
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.